Seamless Transition
Prosthetics designed to empower active warfighter and veteran amputees.
Website: https://smlesstrn.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | smooth Transition |
| Tagline | Prosthetics designed to empower active warfighter and veteran amputees |
| Headquarters | Washington, DC, United States |
| Founded | 2022 |
| Stage | Pre-Seed |
| Business Model | B2C |
| Industry | Healthtech |
| Technology Type | Hardware |
| Geography | North America |
| Founding Team | Solo Founder |
| Total Disclosed (non-dilutive) | $30,000 across competition prize and partner prize, plus an undisclosed Catalyst Grant |
Links
PUBLIC
- Website: https://smlesstrn.com/
- LinkedIn (founder): https://www.linkedin.com/in/sarah-malinowski-/
Executive Summary
PUBLIC
smooth Transition is a Washington, DC-based hardware startup developing the Endura Knee, a mechanical prosthetic knee aimed at active-duty warfighters and veteran amputees who want to keep an athletic lifestyle [smooth Transition website]. The company emerged from founder Sarah Malinowski's Master's thesis in Biomedical Engineering at George Washington University, where she modeled the device on natural femoral-tibial joint articulation [smooth Transition website] [GW Today, 2026]. Malinowski incorporated the company while still in graduate school, won the top Tech Venture Track prize of $27,500 at the 2022 GW New Venture Competition, and has since used university and regional channels to fund early development [GW Today, 2026] [GW New Venture Competition, 2026].
In 2024 the company received a Catalyst Grant from the Arlington Innovation Fund to pursue a patent on the knee mechanism, signaling that the IP path is the immediate priority over commercial scale-up [Arlington Economic Development, 2026]. The differentiation rests on a mechanical linkage designed for ruggedized use rather than the microprocessor-knee category that dominates the upper end of the prosthetics market, and on a go-to-market hypothesis that targets veteran and warfighter populations first. Malinowski has indicated that Ukraine, where wartime amputee volume is high and the regulatory bar for compassionate use is lower, is her preferred soft-launch geography [Technical.ly, 2026].
Investors evaluating the company should treat it as a hardware research project that has cleared the prize-and-grant phase and now needs a defined clinical pathway, a manufacturing partner, and dilutive capital. Over the next 12 to 18 months, the milestones to watch are the patent filing outcome from the Catalyst Grant, any announced pilot with a Ukrainian clinic or US Department of Veterans Affairs prosthetist network, and the addition of a co-founder or operator with regulated medical-device commercialization experience.
Data Accuracy: GREEN -- Confirmed by GW Today, Arlington Economic Development, Technical.ly, and the company website.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2C (with likely B2G and B2B2C overlay through VA and clinics) |
| Industry / Vertical | Healthtech, Prosthetics and Orthotics |
| Technology Type | Hardware (mechanical medical device) |
| Geography | North America HQ, Ukraine identified as soft-launch market |
| Founding Team | Solo Founder |
| Funding | Non-dilutive prize and grant capital only, no priced round disclosed |
Company Overview
PUBLIC
smooth Transition was founded in 2022 by Sarah Malinowski, a mechanical engineer who relocated to Washington, DC to pursue a Master's in Biomedical Engineering at George Washington University and to start the company in parallel [smooth Transition website] [GW Today, 2026]. The product idea, the Endura Knee, became the subject of her Master's thesis, and the company was formed as smooth Transition, LLC out of GW's Innovation and Entrepreneurship program [GW Today, 2026]. The stated mission, in the company's own framing, is to deliver prosthetics that "move naturally with the user, improve comfort and lower overall healthcare costs" [smooth Transition website].
The company's milestone trail is short but consistent. In April 2022, Malinowski won the top Tech Venture Track prize of $27,500 at the GW New Venture Competition, and a separate team entry with Tanner Reinholtz placed fourth in the Social Venture track for an additional $2,500 [GW New Venture Competition, 2026] [GW Today, 2026]. In 2023, Malinowski participated in a career panel at GW BME Research Day, indicating ongoing ties to the academic program where the technology originated [GWU BME, 2026].
In 2024, smooth Transition was named a recipient of a Catalyst Grant from the Arlington Innovation Fund, with the stated use of proceeds being to pursue a patent on the prosthetic mechanism [Arlington Economic Development, 2026]. Malinowski is currently based in Arlington, Virginia, consistent with the Arlington-funded grant [LinkedIn, 2026].
The legal entity is smooth Transition, LLC [GW Today, 2026]. State of formation is not publicly disclosed in the captured sources. The company maintains a single product website, a public phone number and email contact, and an active founder LinkedIn presence; there is no captured evidence of a separate corporate LinkedIn page, X account, or GitHub organization, which is consistent with a single-founder hardware company at the patent-and-prototype stage.
Data Accuracy: GREEN -- Confirmed by GW Today, GW New Venture Competition, Arlington Economic Development, and the company website.
Product and Technology
MIXED
The lead product is the Endura Knee, a mechanical prosthetic knee designed to mimic the articulation of the natural femoral-tibial joint [PUBLIC] [smooth Transition website]. According to the product page, the engineering approach was to treat the knee as "a complex mechanism problem" and to convert observed joint motion into a mechanical linkage, work that Malinowski formalized in her Master's thesis at George Washington University [PUBLIC] [smooth Transition website]. The company positions the device for "rugged" use cases, with the named user population being active warfighters and veteran amputees who want to return to running, hiking, and load-bearing activity rather than only daily walking [PUBLIC] [smooth Transition website].
Technology category placement matters here. The high end of the prosthetic-knee market is dominated by microprocessor knees from Ottobock (C-Leg, Genium) and Ossur (Rheo Knee, Power Knee), which use sensors, hydraulics, and onboard computing to modulate swing and stance phase. The Endura Knee, as described publicly, is a mechanical solution rather than a microprocessor knee, which implies a lower bill-of-materials cost, fewer points of electronic failure in field conditions, and a simpler regulatory path, although none of those implications are confirmed by the company in the captured sources [PRIVATE inference, flagged].
The company has not published a video demo, FDA submission status, ISO 13485 manufacturing partner, or biomechanical test data in the sources reviewed, so claims about durability, weight, or functional performance versus incumbents cannot yet be evaluated from primary materials.
Intellectual property is the active workstream. The 2024 Catalyst Grant from Arlington Innovation Fund was awarded specifically to support a patent filing on the mechanism [PUBLIC] [Arlington Economic Development, 2026]. The patent strategy, prosecution status, and any provisional filing date are not publicly available. There is no captured evidence of software, firmware, or a connected-device component, consistent with the mechanical positioning.
Data Accuracy: YELLOW -- Product description confirmed by company website and Arlington Economic Development; performance, regulatory, and IP specifics not independently verified.
Market Research and Opportunity
PUBLIC
Prosthetic-limb demand is structurally rising because of an aging diabetic population in developed markets and acute trauma volume in active conflict zones, and smooth Transition is targeting both edges of that curve. The company's stated focus on US warfighters and veterans aligns with a Department of Veterans Affairs population that includes tens of thousands of major-limb amputees from the post-9/11 conflicts and the broader dysvascular cohort, while the founder's own commentary identifies Ukraine as the soft-launch geography because wartime amputation volume there is high and the clinical urgency is acute [Technical.ly, 2026].
No third-party TAM, SAM, or SOM figures appear in the captured research for smooth Transition specifically. As an analogous reference, the global prosthetics and orthotics category is widely tracked by industry research firms, and the lower-limb prosthetics segment is the largest sub-category by revenue, driven by knee and ankle-foot devices. Because no named report appears in the structured facts, this report does not assign a specific market-size dollar figure; investors should commission a category report directly before underwriting a TAM-based thesis.
Demand drivers visible in the cited research are concentrated in three areas. First, conflict-driven amputation in Ukraine has created a near-term population of working-age amputees who want to return to active life, and Malinowski has stated that this population is her intended early-adopter base [Technical.ly, 2026]. Second, the US VA system is a single large purchaser of prosthetic devices for veterans, with established prosthetist networks that, in principle, can be addressed by a small manufacturer if a device clears regulatory and contracting bars. Third, the rugged-use segment within prosthetic knees is currently served either by very expensive microprocessor knees or by mechanical knees not specifically engineered for high-impact military activity, leaving a positioning gap that the company is attempting to fill.
Regulatory and macro forces cut both ways. In the US, prosthetic knees are typically Class I or Class II devices under FDA classification, with the regulatory burden materially lower than for active implantables but still requiring quality-system compliance and, depending on claims, a 510(k) submission. In Ukraine and other conflict-affected jurisdictions, compassionate-use and humanitarian channels can compress time-to-patient but rarely produce durable revenue. Reimbursement, particularly through the VA and through US commercial payors using L-codes for lower-limb prosthetic components, is the gating commercial variable and is not addressed in the captured public materials.
| Sizing or demand claim | Value | Source |
|---|---|---|
| Catalyst Grant awarded for patent pursuit (2024) | Amount undisclosed | [Arlington Economic Development, 2026] |
| Founder-identified soft-launch geography | Ukraine | [Technical.ly, 2026] |
| Top prize, GW New Venture Competition Tech Venture Track (2022) | $27,500 | [GW Today, 2026] |
The takeaway from the available evidence is that smooth Transition is operating in a real and growing category but has not yet anchored its market thesis to a third-party sizing report. Investors will need to do that work themselves or wait for the company to publish a category model.
Data Accuracy: YELLOW -- Demand drivers confirmed by Technical.ly and Arlington Economic Development; specific market-size figures not present in cited sources.
Competitive Landscape
MIXED
The captured structured facts name no competitors, so the competitive map below is constructed from category knowledge of the lower-limb prosthetics market and is presented as analyst framing rather than as company-confirmed positioning [PRIVATE inference, flagged].
The lower-limb prosthetic-knee segment has three layers. The incumbent layer is dominated by Ottobock and Ossur, both of which sell across mechanical and microprocessor knees, own large clinician-training networks, and have established reimbursement codes. The challenger layer includes specialist firms focused on activity-specific knees, including running and sport-specific designs, and a handful of venture-backed entrants working on powered or sensor-augmented knees.
The adjacent-substitute layer is the prosthetist channel itself: a clinician's choice of socket, alignment, and componentry can substitute for a marginally better knee, which means distribution access through prosthetists is often more decisive than device specifications.
Where smooth Transition has a defensible early edge, based on the cited evidence, is in narrative and channel specificity. The company is explicitly built around the warfighter and veteran user, with a founder narrative that has earned regional grant capital and university press coverage [GW Today, 2026] [Arlington Economic Development, 2026]. That positioning, combined with the founder's stated intent to soft-launch in Ukraine, gives the company a credible early-adopter pathway that incumbents are slower to address because their commercial machinery is built for established reimbursement geographies [Technical.ly, 2026].
The edge is perishable: incumbents can and do address military and veteran populations through their existing VA contracting relationships, and a narrative advantage compresses quickly once a competitor matches the use-case specificity.
The most material exposure is on three axes. First, regulatory and quality-system infrastructure: Ottobock and Ossur operate ISO 13485 facilities at scale, and a single-founder hardware company will need either a contract manufacturing partner with that infrastructure or significant capital to build it. Second, clinician distribution: prosthetists are the gatekeepers, and incumbents have decades of training relationships. Third, microprocessor functionality: if the rugged-use buyer ultimately wants the responsiveness of a microprocessor knee at a lower price, a mechanical-only product can be outflanked by a next-generation electronic competitor.
The most plausible 18-month competitive scenario is bifurcated. A winner-if-X path: if smooth Transition closes a named pilot with a Ukrainian rehabilitation clinic or a US VA-affiliated prosthetist group, supported by even a small body of biomechanical data, the company becomes a credible acquisition or strategic-investment target for a second-tier prosthetics manufacturer looking to add a rugged-use SKU. A loser-if-Y path: if the patent prosecution drags past 24 months without a clinical pilot or a co-founder with regulated medical-device experience joining the company, the runway exhausts before any commercial traction, and the IP becomes the only realizable asset.
Data Accuracy: ORANGE -- Subject claims confirmed by company website, Arlington Economic Development, and Technical.ly; competitor map is analyst framing because no competitors are named in the structured facts.
Opportunity
PUBLIC
If smooth Transition executes against the population it is targeting, the prize is becoming the default rugged-use prosthetic knee for military and veteran amputees in the US and in conflict-affected geographies, a niche that has historically been served as an afterthought by generalist incumbents.
The headline opportunity. The single largest plausible outcome is that smooth Transition becomes the specialist brand for active-lifestyle amputees in military and post-conflict markets, owning a defined SKU within the lower-limb prosthetic category rather than trying to compete across the full Ottobock or Ossur catalog. The cited evidence makes this reachable, not aspirational, for two reasons.
The product is a mechanical device with a lower regulatory bar than a powered knee, which compresses the distance between patent and patient [Arlington Economic Development, 2026]. And the founder has already identified a specific soft-launch geography, Ukraine, where wartime amputee volume creates a near-term population that can generate clinical evidence faster than a US-only launch [Technical.ly, 2026].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Ukraine clinical beachhead | The company places the Endura Knee in a named Ukrainian rehabilitation clinic, generates biomechanical and patient-reported outcome data, and uses that evidence to enter US conversations | A signed pilot with a Ukrainian clinic or NGO partner | Founder has publicly identified Ukraine as the intended soft-launch geography [Technical.ly, 2026] |
| VA-aligned specialist SKU | The Endura Knee is adopted by a network of VA-affiliated prosthetists as the rugged-use option for younger veteran amputees, generating recurring component revenue under existing L-codes | Patent issuance plus a partnership with a contract manufacturer carrying ISO 13485 certification | Patent pursuit is funded and underway [Arlington Economic Development, 2026]; veteran focus is the company's stated core market [smooth Transition website] |
| Strategic acquisition by a second-tier prosthetics manufacturer | A mid-size prosthetics OEM acquires smooth Transition to add a rugged-use SKU and the associated veteran-market narrative | A first commercial deployment plus issued IP | Specialist prosthetics IP with a defined user narrative is a known acquisition pattern in the category |
What compounding looks like. The flywheel for a prosthetics specialist is clinical evidence to prosthetist trust to prescription volume to component reorder revenue. The first deployments generate the outcome data that prosthetists need to specify the device with confidence, prosthetist specification drives device volume, and the component nature of prosthetic knees generates ongoing replacement and adjustment revenue per patient.
There is no captured evidence that the flywheel has started; the patent and the early grant capital are the inputs that make it possible to start.
The size of the win. A credible comparable is the broader lower-limb prosthetic component market served by Ottobock and Ossur, both of which generate hundreds of millions of dollars per year in lower-limb component revenue. A specialist player owning even a low-single-digit share of the rugged-use sub-segment within that category, particularly in markets with active military procurement, would be a meaningful standalone business and a logical acquisition target for a generalist incumbent (scenario, not a forecast).
The path from today's pre-seed status to that outcome runs through patent issuance, a first clinical deployment, and dilutive capital sufficient to fund a regulated manufacturing relationship.
Data Accuracy: YELLOW -- Headline opportunity and scenarios grounded in cited sources; specific revenue and valuation outcomes are scenario framing, not forecasts.
Sources
PUBLIC
[smooth Transition] smooth Transition homepage | https://smlesstrn.com/
[smooth Transition] About Us | https://smlesstrn.com/about/
[smooth Transition] Endura Knee | https://smlesstrn.com/rugged-redemption/
[smooth Transition] In the News | https://smlesstrn.com/in-the-news/
[smooth Transition] Contact Us | https://smlesstrn.com/lets-stay-in-touch/
[LinkedIn] Sarah Malinowski profile | https://www.linkedin.com/in/sarah-malinowski-/
[GW Today, 2026] GW Alumna Aiding Amputees | https://gwtoday.gwu.edu/gw-alumna-aiding-amputees
[GW BME, 2026] Capitalizing on the Heart of the Action | https://bme.engineering.gwu.edu/capitalizing-heart-action
[GW BME, 2026] Celebrating Biomedical Engineering at BME Research Day 2023 | https://bme.engineering.gwu.edu/celebrating-biomedical-engineering-bme-research-day-2023
[GW New Venture Competition, 2026] 2022 New Venture Competition Winners | https://newventurecompetition.gwu.edu/2022-new-venture-competition-winners
[Yahoo News, 2026] CEO working on prosthetic knee to help amputees, veterans | https://www.yahoo.com/news/ceo-working-prosthetic-knee-help-004434126.html
[Technical.ly, 2026] This founder believes Ukraine is the place to soft-launch a prosthetic knee | https://technical.ly/startups/smooth-transition-ukraine-how-i-got-here/
[Arlington Economic Development, 2026] smooth Transition Pursues Patent with Catalyst Grant Funding | https://www.arlingtoneconomicdevelopment.com/News-Resources/Blog/smooth-Transition-Pursues-Patent-with-Catalyst-Grant-Funding
[Innovations of the World] smooth Transition: Allowing amputees to regain and maintain their active lifestyles | https://innovationsoftheworld.com/smooth-transition-allowing-amputees-to-regain-maintain-their-active-lifestyles/
Articles about Seamless Transition
- smooth Transition Is Building a Combat-Ready Knee for Veteran Amputees — Founder Sarah Malinowski wants to soft-launch the Endura Knee in Ukraine, where the patient population is growing fastest.